PPM1G and its diagnostic, prognostic and therapeutic potential in HCC (Review)

Zhang,Xiaomin; Wang,Heyue; Yuan,Yiran; Zhang,Jieya; Yang,Jize; Zhang,Lei; He,Jiefeng

doi:10.3892/ijo.2024.5697

PPM1G and its diagnostic, prognostic and therapeutic potential in HCC (Review)

Authors:
- Xiaomin Zhang
- Heyue Wang
- Yiran Yuan
- Jieya Zhang
- Jize Yang
- Lei Zhang
- Jiefeng He
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, Shanxi 030032, P.R. China
Published online on: September 23, 2024 https://doi.org/10.3892/ijo.2024.5697
Article Number: 109
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Global statistics indicate that hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer‑related death. Protein phosphatase Mg²⁺/Mn²⁺ dependent 1G (PPM1G, also termed PP2Cγ) is one of the 17 members of the PPM family. The enzymatic activity of PPM1G is highly reliant on Mg²⁺ or Mn²⁺ and serves as a dephosphorylation regulator for numerous key proteins. PPM1G, functioning as a phosphatase, is involved in a number of significant biological processes such as the regulation of eukaryotic gene expression, DNA damage response, cell cycle and apoptosis, cell migration ability, cell survival and embryonic nervous system development. Additionally, PPM1G serves a role in regulating various signaling pathways. In recent years, further research has increasingly highlighted PPM1G as an oncogene in HCC. A high expression level of PPM1G is closely associated with the occurrence, progression and poor prognosis of HCC, offering notable diagnostic and therapeutic value for this patient population. In the present review, the regulatory role of PPM1G in diverse biological processes and signaling pathway activation in eukaryotes is evaluated. Furthermore, its potential application as a biomarker in the diagnosis and prognosis evaluation of HCC is assessed, and future prospects for HCC treatment strategies centered on PPM1G are discussed.

View Figures

View References

1	Zhang X, Wang Z, Tang W, Wang X, Liu R, Bao H, Chen X, Wei Y, Wu S, Bao H, et al: Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics. Hepatology. 76:317–329. 2022. View Article : Google Scholar
2	Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, Wei W, Lemmens VEPP and Soerjomataram I: Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 161:108–118. 2022. View Article : Google Scholar
3	Feng M, Pan Y, Kong R and Shu S: Therapy of primary liver cancer. Innovation (Camb). 1:1000322020.
4	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
5	Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA and Soerjomataram I: Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 77:1598–1606. 2022. View Article : Google Scholar : PubMed/NCBI
6	Stroffolini T and Stroffolini G: A historical overview on the role of hepatitis B and C viruses as aetiological factors for hepatocellular carcinoma. Cancers (Basel). 15:23882023. View Article : Google Scholar
7	Foerster F, Gairing SJ, Müller L and Galle PR: NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol. 76:446–457. 2022. View Article : Google Scholar
8	Huang KY, Su MG, Kao HJ, Hsieh YC, Jhong JH, Cheng KH, Huang HD and Lee TY: dbPTM 2016: 10-Year anniversary of a resource for post-translational modification of proteins. Nucleic Acids Res. 44(D1): D435–D446. 2016. View Article : Google Scholar :
9	Ebert T, Tran N, Schurgers L, Stenvinkel P and Shiels PG: Ageing-oxidative stress, PTMs and disease. Mol Aspects Med. 86:1010992022. View Article : Google Scholar
10	Zafar S, Fatima SI, Schmitz M and Zerr I: Current technologies unraveling the significance of post-translational modifications (PTMs) as crucial players in neurodegeneration. Biomolecules. 14:1182024. View Article : Google Scholar : PubMed/NCBI
11	Wang Y, Liu Z, Bian X, Zhao C, Zhang X, Liu X and Wang N: Function and regulation of ubiquitin-like SUMO system in heart. Front Cell Dev Biol. 11:12947172023. View Article : Google Scholar : PubMed/NCBI
12	Chen L, Huang L, Gu Y, Cang W, Sun P and Xiang Y: lactate-lactylation hands between metabolic reprogramming and immunosuppression. Int J Mol Sci. 23:119432022. View Article : Google Scholar : PubMed/NCBI
13	Safabakhsh S, Panwar P, Barichello S, Sangha SS, Hanson PJ, Petegem FV and Laksman Z: The role of phosphorylation in atrial fibrillation: A focus on mass spectrometry approaches. Cardiovasc Res. 118:1205–1217. 2022. View Article : Google Scholar
14	Song W, Hu L, Ma Z, Yang L and Li J: Importance of tyrosine phosphorylation in hormone-regulated plant growth and development. Int J Mol Sci. 23:66032022. View Article : Google Scholar : PubMed/NCBI
15	Stanford SM and Bottini N: Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders. Nat Rev Drug Discov. 22:273–294. 2023. View Article : Google Scholar : PubMed/NCBI
16	Gao C, Cao N and Wang Y: Metal dependent protein phosphatase PPM family in cardiac health and diseases. Cell Signal. 85:1100612021. View Article : Google Scholar : PubMed/NCBI
17	Kamada R, Kudoh F, Ito S, Tani I, Janairo JIB, Omichinski JG and Sakaguchi K: Metal-dependent Ser/Thr protein phosphatase PPM family: Evolution, structures, diseases and inhibitors. Pharmacol Ther. 215:1076222020. View Article : Google Scholar : PubMed/NCBI
18	Das AK, Helps NR, Cohen PT and Barford D: Crystal structure of the protein serine/threonine phosphatase 2C at 2.0 A resolution. EMBO J. 15:6798–6809. 1996. View Article : Google Scholar : PubMed/NCBI
19	Pan C, Tang JY, Xu YF, Xiao P, Liu HD, Wang HA, Wang WB, Meng FG, Yu X and Su JP: The catalytic role of the M2 metal ion in PP2Cα. Sci Rep. 5:85602015. View Article : Google Scholar
20	The GeneCards human gene database: Weizmann Institute of Science; [updated 30-5-2024]. Available from: www.genecards.org/Search/Keyword?queryString=PPM1G.
21	Travis SM and Welsh MJ: PP2C gamma: A human protein phosphatase with a unique acidic domain. FEBS Lett. 412:415–419. 1997. View Article : Google Scholar : PubMed/NCBI
22	Chen D, Zhao Z, Chen L, Li Q, Zou J and Liu S: PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3. Cell Death Dis. 12:7222021. View Article : Google Scholar : PubMed/NCBI
23	Mandal R, Becker S and Strebhardt K: Targeting CDK9 for anti-cancer therapeutics. Cancers (Basel). 13:31812021. View Article : Google Scholar
24	Whelan M and Pelchat M: Role of RNA polymerase II promoter-proximal pausing in viral transcription. Viruses. 14:20292022. View Article : Google Scholar : PubMed/NCBI
25	Tellier M, Zaborowska J, Neve J, Nojima T, Hester S, Fournier M, Furger A and Murphy S: CDK9 and PP2A regulate RNA polymerase II transcription termination and coupled RNA maturation. EMBO Rep. 23:e545202022. View Article : Google Scholar : PubMed/NCBI
26	Fujinaga K, Huang F and Peterlin BM: P-TEFb: The master regulator of transcription elongation. Mol Cell. 83:393–403. 2023. View Article : Google Scholar : PubMed/NCBI
27	Yamayoshi A, Fukumoto H, Hayashi R, Kishimoto K, Kobori A, Koyanagi Y, Komano JA and Murakami A: Development of 7SK snRNA mimics that inhibit HIV transcription. ChemMedChem. 16:3181–3184. 2021. View Article : Google Scholar : PubMed/NCBI
28	McNamara RP, McCann JL, Gudipaty SA and D'Orso I: Transcription factors mediate the enzymatic disassembly of promoter-bound 7SK snRNP to locally recruit P-TEFb for transcription elongation. Cell Rep. 5:1256–1268. 2013. View Article : Google Scholar : PubMed/NCBI
29	Gudipaty SA, McNamara RP, Morton EL and D'Orso I: PPM1G binds 7SK RNA and Hexim1 to block P-TEFb assembly into the 7SK snRNP and sustain transcription elongation. Mol Cell Biol. 35:3810–3828. 2015. View Article : Google Scholar : PubMed/NCBI
30	Gudipaty SA and D'Orso I: Functional interplay between PPM1G and the transcription elongation machinery. RNA Dis. 3:e12152016.PubMed/NCBI
31	Bagashev A and Sawaya BE: Roles and functions of HIV-1 Tat protein in the CNS: an overview. Virol J. 10:3582013. View Article : Google Scholar : PubMed/NCBI
32	Mbonye U, Wang B, Gokulrangan G, Shi W, Yang S and Karn J: Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation. J Biol Chem. 293:10009–10025. 2018. View Article : Google Scholar : PubMed/NCBI
33	Schulze-Gahmen U and Hurley JH: Structural mechanism for HIV-1 TAR loop recognition by Tat and the super elongation complex. Proc Natl Acad Sci USA. 115:12973–12978. 2018. View Article : Google Scholar : PubMed/NCBI
34	Hluchý M, Gajdušková P, Ruiz de Los Mozos I, Rájecký M, Kluge M, Berger BT, Slabá Z, Potěšil D, Weiß E, Ule J, et al: CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1. Nature. 609:829–834. 2022. View Article : Google Scholar : PubMed/NCBI
35	Borišek J, Casalino L, Saltalamacchia A, Mays SG, Malcovati L and Magistrato A: Atomic-level mechanism of pre-mRNA splicing in health and disease. Acc Chem Res. 54:144–154. 2021. View Article : Google Scholar
36	Ule J and Blencowe BJ: Alternative splicing regulatory networks: Functions, mechanisms, and evolution. Mol Cell. 76:329–345. 2019. View Article : Google Scholar : PubMed/NCBI
37	Murray MV, Kobayashi R and Krainer AR: The type 2C Ser/Thr phosphatase PP2Cgamma is a pre-mRNA splicing factor. Genes Dev. 13:87–97. 1999. View Article : Google Scholar : PubMed/NCBI
38	Allemand E, Hastings ML, Murray MV, Myers MP and Krainer AR: Alternative splicing regulation by interaction of phosphatase PP2Cgamma with nucleic acid-binding protein YB-1. Nat Struct Mol Biol. 14:630–638. 2007. View Article : Google Scholar : PubMed/NCBI
39	Wu S and Wagner G: Computational inference of eIF4F complex function and structure in human cancers. Proc Natl Acad Sci USA. 121:e23135891212024. View Article : Google Scholar : PubMed/NCBI
40	Jia X, He X, Huang C, Li J, Dong Z and Liu K: Protein translation: Biological processes and therapeutic strategies for human diseases. Signal Transduct Target Ther. 9:442024. View Article : Google Scholar : PubMed/NCBI
41	Thompson L, Depledge DP, Burgess HM and Mohr I: An eIF3d-dependent switch regulates HCMV replication by remodeling the infected cell translation landscape to mimic chronic ER stress. Cell Rep. 39:1107672022. View Article : Google Scholar : PubMed/NCBI
42	Liu J, Stevens PD, Eshleman NE and Gao T: Protein phosphatase PPM1G regulates protein translation and cell growth by dephosphorylating 4E binding protein 1 (4E-BP1). J Biol Chem. 288:23225–23233. 2013. View Article : Google Scholar : PubMed/NCBI
43	Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R and Sonenberg N: Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15:2852–2864. 2001. View Article : Google Scholar : PubMed/NCBI
44	Takahashi S, Shibutani S and Iwata H: Nuclear-targeted 4E-BP1 is dephosphorylated, induces nuclear translocation of eIF4E, and alters mRNA translation. Exp Cell Res. 418:1132462022. View Article : Google Scholar : PubMed/NCBI
45	Xu K, Wang L, Feng W, Feng Y and Shu HK: Phosphatidylinositol-3 kinase-dependent translational regulation of Id1 involves the PPM1G phosphatase. Oncogene. 35:5807–5816. 2016. View Article : Google Scholar : PubMed/NCBI
46	Sultana S, Zarreen F and Chakraborty S: Insights into the roles of histone chaperones in nucleosome assembly and disassembly in virus infection. Virus Res. 297:1983952021. View Article : Google Scholar : PubMed/NCBI
47	Li S, Edwards G, Radebaugh CA, Luger K and Stargell LA: Spn1 and its dynamic interactions with Spt6, histones and nucleosomes. J Mol Biol. 434:1676302022. View Article : Google Scholar : PubMed/NCBI
48	Lian Y, Hao H, Xu J, Bo T, Liang A and Wang W: The histone chaperone Nrp1 is required for chromatin stability and nuclear division in Tetrahymena thermophila. Epigenetics Chromatin. 14:342021. View Article : Google Scholar : PubMed/NCBI
49	Kimura H, Takizawa N, Allemand E, Hori T, Iborra FJ, Nozaki N, Muraki M, Hagiwara M, Krainer AR, Fukagawa T and Okawa K: A novel histone exchange factor, protein phosphatase 2Cgamma, mediates the exchange and dephosphorylation of H2A-H2B. J Cell Biol. 175:389–400. 2006. View Article : Google Scholar : PubMed/NCBI
50	Luo Q, Wang B, Wu Z, Jiang W, Wang Y, Du K, Zhou N, Zheng L, Gan J, Shen WH, et al: NAP1-Related Protein 1 (NRP1) has multiple interaction modes for chaperoning histones H2A-H2B. Proc Natl Acad Sci USA. 117:30391–30399. 2020. View Article : Google Scholar : PubMed/NCBI
51	Farrugia M, Vassallo N and Cauchi RJ: Disruption of survival motor neuron in glia impacts survival but has no effect on neuromuscular function in Drosophila. Neuroscience. 491:32–42. 2022. View Article : Google Scholar : PubMed/NCBI
52	Riboldi GM, Faravelli I, Kuwajima T, Delestrée N, Dermentzaki G, De Planell-Saguer M, Rinchetti P, Hao LT, Beattie CC, Corti S, et al: Sumoylation regulates the assembly and activity of the SMN complex. Nat Commun. 12:50402021. View Article : Google Scholar : PubMed/NCBI
53	Musawi S, Donnio LM, Zhao Z, Magnani C, Rassinoux P, Binda O, Huang J, Jacquier A, Coudert L, Lomonte P, et al: Nucleolar reorganization after cellular stress is orchestrated by SMN shuttling between nuclear compartments. Nat Commun. 14:73842023. View Article : Google Scholar : PubMed/NCBI
54	Franco-Espin J, Gatius A, Armengol JÁ, Arumugam S, Moradi M, Sendtner M, Calderó J and Tabares L: SMN is physiologically downregulated at wild-type motor nerve terminals but aggregates together with neurofilaments in SMA mouse models. Biomolecules. 12:15242022. View Article : Google Scholar : PubMed/NCBI
55	Petri S, Grimmler M, Over S, Fischer U and Gruss OJ: Dephosphorylation of survival motor neurons (SMN) by PPM1G/PP2Cgamma governs Cajal body localization and stability of the SMN complex. J Cell Biol. 179:451–465. 2007. View Article : Google Scholar : PubMed/NCBI
56	Detering NT, Schüning T, Hensel N and Claus P: The phospho-landscape of the survival of motoneuron protein (SMN) protein: Relevance for spinal muscular atrophy (SMA). Cell Mol Life Sci. 79:4972022. View Article : Google Scholar : PubMed/NCBI
57	Husedzinovic A, Neumann B, Reymann J, Draeger-Meurer S, Chari A, Erfle H, Fischer U and Gruss OJ: The catalytically inactive tyrosine phosphatase HD-PTP/PTPN23 is a novel regulator of SMN complex localization. Mol Biol Cell. 26:161–171. 2015. View Article : Google Scholar :
58	Martinez-Salas E, Embarc-Buh A and Francisco-Velilla R: Emerging roles of Gemin5: From snRNPs assembly to translation control. Int J Mol Sci. 21:38682020. View Article : Google Scholar : PubMed/NCBI
59	Hu Y, Hou Y, Zhou S, Wang Y, Shen C, Mu L, Su D and Zhang R: Mechanism of assembly of snRNP cores assisted by ICln and the SMN complex in fission yeast. iScience. 26:1076042023. View Article : Google Scholar : PubMed/NCBI
60	Oksenych V and Kainov DE: DNA damage response. Biomolecules. 11:1232021. View Article : Google Scholar : PubMed/NCBI
61	Santivasi WL and Xia F: Ionizing radiation-induced DNA damage, response, and repair. Antioxid Redox Signal. 21:251–259. 2014. View Article : Google Scholar
62	Ciccia A and Elledge SJ: The DNA damage response: Making it safe to play with knives. Mol Cell. 40:179–204. 2010. View Article : Google Scholar : PubMed/NCBI
63	Georgoulis A, Vorgias CE, Chrousos GP and Rogakou EP: Genome instability and γH2AX. Int J Mol Sci. 18:19792017. View Article : Google Scholar
64	Beli P, Lukashchuk N, Wagner SA, Weinert BT, Olsen JV, Baskcomb L, Mann M, Jackson SP and Choudhary C: Proteomic investigations reveal a role for RNA processing factor THRAP3 in the DNA damage response. Mol Cell. 46:212–225. 2012. View Article : Google Scholar : PubMed/NCBI
65	Khoronenkova SV, Dianova II, Ternette N, Kessler BM, Parsons JL and Dianov GL: ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage. Mol Cell. 45:801–813. 2012. View Article : Google Scholar : PubMed/NCBI
66	Koo N, Sharma AK and Narayan S: Therapeutics targeting p53-MDM2 interaction to induce cancer cell death. Int J Mol Sci. 23:50052022. View Article : Google Scholar : PubMed/NCBI
67	Williams AB and Schumacher B: p53 in the DNA-damage-repair process. Cold Spring Harb Perspect Med. 6:a0260702016. View Article : Google Scholar : PubMed/NCBI
68	Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER III, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, et al: ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 316:1160–1166. 2007. View Article : Google Scholar : PubMed/NCBI
69	Khoronenkova SV and Dianov GL: Regulation of USP7/HAUSP in response to DNA damage: Yet another role for ATM. Cell Cycle. 11:2409–2410. 2012. View Article : Google Scholar : PubMed/NCBI
70	Chaudhary N and Maddika S: WWP2-WWP1 ubiquitin ligase complex coordinated by PPM1G maintains the balance between cellular p73 and ΔNp73 levels. Mol Cell Biol. 34:3754–3764. 2014. View Article : Google Scholar : PubMed/NCBI
71	Chen X, Ma J, Wang ZW and Wang Z: The E3 ubiquitin ligases regulate inflammation in cardiovascular diseases. Semin Cell Dev Biol. 154:167–174. 2024. View Article : Google Scholar
72	Wang Y, Wu Z, Wang C, Wu N, Wang C, Hu S and Shi J: The role of WWP1 and WWP2 in bone/cartilage development and diseases. Mol Cell Biochem. Jan 22–2024.Epub ahead of print.
73	Yoon MK, Ha JH, Lee MS and Chi SW: Structure and apoptotic function of p73. BMB Rep. 48:81–90. 2015. View Article : Google Scholar :
74	Osterburg C and Dötsch V: Structural diversity of p63 and p73 isoforms. Cell Death Differ. 29:921–937. 2022. View Article : Google Scholar : PubMed/NCBI
75	Engeland K: Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 29:946–960. 2022. View Article : Google Scholar : PubMed/NCBI
76	Kuganesan N, Dlamini S, Tillekeratne LMV and Taylor WR: Tumor suppressor p53 promotes ferroptosis in oxidative stress conditions independent of modulation of ferroptosis by p21, CDKs, RB, and E2F. J Biol Chem. 297:1013652021. View Article : Google Scholar : PubMed/NCBI
77	Suh EJ, Kim TY and Kim SH: PP2Cgamma-mediated S-phase accumulation induced by the proteasome-dependent degradation of p21(WAF1/CIP1). FEBS Lett. 580:6100–6104. 2006. View Article : Google Scholar : PubMed/NCBI
78	Desvoyes B and Gutierrez C: Roles of plant retinoblastoma protein: Cell cycle and beyond. EMBO J. 39:e1058022020. View Article : Google Scholar : PubMed/NCBI
79	Sanidas I, Morris R, Fella KA, Rumde PH, Boukhali M, Tai EC, Ting DT, Lawrence MS, Haas W and Dyson NJ: A code of mono-phosphorylation modulates the function of RB. Mol Cell. 73:985–1000.e6. 2019. View Article : Google Scholar : PubMed/NCBI
80	Sharma SS and Pledger WJ: The non-canonical functions of p27(Kip1) in normal and tumor biology. Cell Cycle. 15:1189–1201. 2016. View Article : Google Scholar : PubMed/NCBI
81	Deshmukh D, Xu J, Yang X, Shimelis H, Fang S and Qiu Y: Regulation of p27 (Kip1) by ubiquitin E3 ligase RNF6. Pharmaceutics. 14:8022022. View Article : Google Scholar : PubMed/NCBI
82	Cassimere EK, Mauvais C and Denicourt C: p27Kip1 is required to mediate a G1 cell cycle arrest downstream of ATM following genotoxic stress. PLoS One. 11:e01628062016. View Article : Google Scholar : PubMed/NCBI
83	Fujita N, Sato S, Katayama K and Tsuruo T: Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem. 277:28706–28713. 2002. View Article : Google Scholar : PubMed/NCBI
84	Sun C, Wang G, Wrighton KH, Lin H, Songyang Z, Feng XH and Lin X: Regulation of p27^Kip1 phosphorylation and G1 cell cycle progression by protein phosphatase PPM1G. Am J Cancer Res. 6:2207–2220. 2016.
85	Sousa B, Pereira J and Paredes J: The crosstalk between cell adhesion and cancer metabolism. Int J Mol Sci. 20:19332019. View Article : Google Scholar : PubMed/NCBI
86	Sun Y, Zhang J and Ma L: α-Catenin. A tumor suppressor beyond adherens junctions. Cell Cycle. 13:2334–2339. 2014. View Article : Google Scholar :
87	Lessey LR, Robinson SC, Chaudhary R and Daniel JM: Adherens junction proteins on the move-from the membrane to the nucleus in intestinal diseases. Front Cell Dev Biol. 10:9983732022. View Article : Google Scholar : PubMed/NCBI
88	Duong CN, Brückner R, Schmitt M, Nottebaum AF, Braun LJ, Meyer Zu Brickwedde M, Ipe U, Vom Bruch H, Schöler HR, Trapani G, et al: Force-induced changes of α-catenin conformation stabilize vascular junctions independently of vinculin. J Cell Sci. 134:jcs2590122021. View Article : Google Scholar
89	Kumar P, Tathe P, Chaudhary N and Maddika S: PPM1G forms a PPP-type phosphatase holoenzyme with B56δ that maintains adherens junction integrity. EMBO Rep. 20:e469652019. View Article : Google Scholar
90	Foster WH, Langenbacher A, Gao C, Chen J and Wang Y: Nuclear phosphatase PPM1G in cellular survival and neural development. Dev Dyn. 242:1101–1109. 2013. View Article : Google Scholar : PubMed/NCBI
91	Chen J, Li J, Sun H, Hu T, Wang Y, Kang G, Cao M and Li X: PPM1G promotes the progression of lung adenocarcinoma by inhibiting p38 activation via dephosphorylation of MEK6. Carcinogenesis. 44:93–104. 2023. View Article : Google Scholar
92	Kim EK and Choi EJ: Compromised MAPK signaling in human diseases: An update. Arch Toxicol. 89:867–882. 2015. View Article : Google Scholar : PubMed/NCBI
93	Di Rocco A, Camero S, Benedetti A, Lozanoska-Ochser B, Megiorni F, Marchese C, Stramucci L, Ciccarelli C, Bouché M, Bossi G, et al: Anti-oncogenic and pro-myogenic action of the MKK6/p38/AKT axis induced by targeting MEK/ERK in embryonal rhabdomyosarcoma. Oncol Rep. 48:1512022. View Article : Google Scholar :
94	Martínez-Limón A, Joaquin M, Caballero M, Posas F and de Nadal E: The p38 pathway: From biology to cancer therapy. Int J Mol Sci. 21:19132020. View Article : Google Scholar :
95	Ming Z, Lim SY and Rizos H: Genetic alterations in the INK4a/ARF locus: Effects on melanoma development and progression. Biomolecules. 10:14472020. View Article : Google Scholar : PubMed/NCBI
96	Hyder U, McCann JL, Wang J, Fung V, Bayo J and D'Orso I: The ARF tumor suppressor targets PPM1G/PP2Cγ to counteract NF-κB transcription tuning cell survival and the inflammatory response. Proc Natl Acad Sci USA. 117:32594–32605. 2020. View Article : Google Scholar
97	Roschger C and Cabrele C: The Id-protein family in developmental and cancer-associated pathways. Cell Commun Signal. 15:72017. View Article : Google Scholar : PubMed/NCBI
98	Xiong DL, Li Q, Wang H, Jin WL, Fan XM and Ma YY: High expression of PPM1G is associated with the progression and poor prognosis of hepatocellular carcinoma. Cancer Biomark. 34:13–22. 2022. View Article : Google Scholar
99	Hu W, Ma SL, Qiong L, Du Y, Gong LP, Pan YH, Sun LP, Wen JY, Chen JN, Guan XY and Shao CK: PPM1G promotes cell proliferation via modulating mutant GOF p53 protein expression in hepatocellular carcinoma. iScience. 27:1091162024. View Article : Google Scholar : PubMed/NCBI
100	Liu X, Zeng J, Li H, Li F, Jiang B, Zhao M, Liu Z, Li R and Ma T: A risk model based on sorafenib-response target genes predicts the prognosis of patients with HCC. J Oncol. 2022:72577382022.PubMed/NCBI
101	Li W, Liu J, Zhang D, Gu L and Zhao H: The prognostic significance and potential mechanism of ferroptosis-related genes in hepatocellular carcinoma. Front Genet. 13:8446242022. View Article : Google Scholar : PubMed/NCBI
102	Yang H, Huo J and Li X: Identification and validation of a five-gene prognostic signature for hepatocellular carcinoma. World J Surg Oncol. 19:902021. View Article : Google Scholar : PubMed/NCBI
103	Li W, Lu J, Ma Z, Zhao J and Liu J: An integrated model based on a six-gene signature predicts overall survival in patients with hepatocellular carcinoma. Front Genet. 10:13232020. View Article : Google Scholar : PubMed/NCBI
104	Zhang BH, Yang J, Jiang L, Lyu T, Kong LX, Tan YF, Li B, Zhu YF, Xi AY, Xu X, et al: Development and validation of a 14-gene signature for prognosis prediction in hepatocellular carcinoma. Genomics. 112:2763–2771. 2020. View Article : Google Scholar : PubMed/NCBI
105	Jia R and Zheng ZM: Oncogenic SRSF3 in health and diseases. Int J Biol Sci. 19:3057–3076. 2023. View Article : Google Scholar :
106	Sen S, Langiewicz M, Jumaa H and Webster NJG: Deletion of serine/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice. Hepatology. 61:171–183. 2015. View Article : Google Scholar
107	Wen C, Tian Z, Li L, Chen T, Chen H, Dai J, Liang Z, Ma S and Liu X: SRSF3 and HNRNPH1 regulate radiation-induced alternative splicing of protein arginine methyltransferase 5 in hepatocellular carcinoma. Int J Mol Sci. 23:148322022. View Article : Google Scholar : PubMed/NCBI
108	Hong B, van den Heuvel AP, Prabhu VV, Zhang S and El-Deiry WS: Targeting tumor suppressor p53 for cancer therapy: Strategies, challenges and opportunities. Curr Drug Targets. 15:80–89. 2014. View Article : Google Scholar : PubMed/NCBI
109	Zhang C, Liu J, Xu D, Zhang T, Hu W and Feng Z: Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 12:674–687. 2020. View Article : Google Scholar : PubMed/NCBI
110	Zhao M, Wang T, Gleber-Netto FO, Chen Z, McGrail DJ, Gomez JA, Ju W, Gadhikar MA, Ma W, Shen L, et al: Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response. Nat Commun. 15:1802024. View Article : Google Scholar : PubMed/NCBI
111	Roehlen N, Crouchet E and Baumert TF: Liver fibrosis: Mechanistic concepts and therapeutic perspectives. Cells. 9:8752020. View Article : Google Scholar : PubMed/NCBI
112	Ge MX, Liu HT, Zhang N, Niu WX, Lu ZN, Bao YY, Huang R, Yu DK, Shao RG and He HW: Costunolide represses hepatic fibrosis through WW domain-containing protein 2-mediated Notch3 degradation. Br J Pharmacol. 177:372–387. 2020. View Article : Google Scholar
113	Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, et al: BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 76:681–693. 2022. View Article : Google Scholar :
114	Guan Y, Yao W, Yi K, Zheng C, Lv S, Tao Y, Hei Z and Li M: Nanotheranostics for the management of hepatic ischemia-reperfusion injury. Small. 17:e20077272021. View Article : Google Scholar : PubMed/NCBI
115	Peng D, Huang Z, Yang H, Luo Y and Wu Z: PPM1G regulates hepatic ischemia/reperfusion injury through STING-mediated inflammatory pathways in macrophages. Immun Inflamm Dis. 12:e11892024. View Article : Google Scholar
116	Yu K, Tian H and Deng H: PPM1G restricts innate immune signaling mediated by STING and MAVS and is hijacked by KSHV for immune evasion. Sci Adv. 6:eabd02762020. View Article : Google Scholar : PubMed/NCBI
117	Ho SY, Chang CM, Liao HN, Chou WH, Guo CL, Yen Y, Nakamura Y and Chang WC: Current trends in neoantigen-based cancer vaccines. Pharmaceuticals (Basel). 16:3922023. View Article : Google Scholar : PubMed/NCBI
118	Fu J, Chen F, Lin Y, Gao J, Chen A and Yang J: Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development. J Cancer Res Clin Oncol. 149:4047–4061. 2023. View Article : Google Scholar
119	Wang B, Pei J, Xu S, Liu J and Yu J: Recent advances in mRNA cancer vaccines: Meeting challenges and embracing opportunities. Front Immunol. 14:12466822023. View Article : Google Scholar : PubMed/NCBI
120	Lu TL, Li CL, Gong YQ, Hou FT and Chen CW: Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development. World J Gastrointest Oncol. 15:1717–1738. 2023. View Article : Google Scholar : PubMed/NCBI